Drug pipeline, clinical trials, and major challenges to overcome in Alzheimer’s disease

Well SupportedMost Alzheimer's drugs in development target disease modification.

Not SupportedSome medications targeting Alzheimer's have caused significant medical issues such as liver toxicity or cardiac arrhythmias.

Partially SupportedPathologic amyloid, such as abnormal lengths of A-beta 40 and 42, can be removed without consequence as it should not be present in the body.

Partially SupportedCurrent Alzheimer's drugs like donepezil, galantamine, rivastigmine, and memantine help with neurotransmitters but do not target the underlying pathology of amyloid and tau.

Partially SupportedAbnormal amyloid beta lengths (40 or 42 amino acids) lead to misfolding, fibril formation, and plaque aggregation in the brain.